Young female patients had a mean baseline EF of 58.3 compared with 75 for older male patients. Additionally, emotional function scores varied by disease type. When divided by cancer type and sex, the ...
Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...
The concept of adjuvant therapy for cancer was developed at a time when systemic cancer treatment was limited to cytotoxic chemotherapy that could only be administered intermittently but rarely ...
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...
The MANEUVER trial was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib in unresectable TGCT patients. Pimicotinib shows promising long-term efficacy in treating ...
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) ...
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...
A 2025 report published in the American Medical Association journal JAMA found that moms of children ages 0-17 are ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that at the 2025 European Society for Medical ...
We speak to a doctor about inflammatory bowel disease to understand more about the condition, from the signs and symptoms to the treatments that are available today ...
The potent and selective HIF-2a inhibitor belzutifan is a treatment option for advanced RCC following prior anti-PD- (L)1 and VEGFR-TKI therapy and may be a highly suitable candidate for novel triplet ...